Target Prioritization on BRAF inhibitor case study A375 cell line, Vemurafenib
1Target Rank
PBIO-AGENT-8B
Updated 3mo ago
Evaluation Results
| Method | Links | |||
|---|---|---|---|---|
2026.02 | 1 | 0.177 | 64.6 | |
2026.02 | 2 | 0.029 | 5.1 | |
2026.02 | 2 | -0.025 | -28.1 |
PBIO-AGENT-8B
| Method | Links | |||
|---|---|---|---|---|
2026.02 | 1 | 0.177 | 64.6 | |
2026.02 | 2 | 0.029 | 5.1 | |
2026.02 | 2 | -0.025 | -28.1 |